The DNA methyltransferase inhibitor, guadecitabine, targets tumor-induced myelopoiesis and recovers T cell activity to slow tumor growth in combination with adoptive immunotherapy in a mouse model of breast cancer

BACKGROUND: Myeloid derived suppressor cells (MDSCs) present a significant obstacle to cancer immunotherapy because they dampen anti-tumor cytotoxic T cell responses. Previous groups, including our own, have reported on the myelo-depletive effects of certain chemotherapy agents. We have shown previo...

Descripción completa

Detalles Bibliográficos
Autores principales: Luker, Andrea J., Graham, Laura J., Smith, Timothy M., Camarena, Carmen, Zellner, Matt P., Gilmer, Jamie-Jean S., Damle, Sheela R., Conrad, Daniel H., Bear, Harry D., Martin, Rebecca K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045411/
https://www.ncbi.nlm.nih.gov/pubmed/32106810
http://dx.doi.org/10.1186/s12865-020-0337-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045411/
https://www.ncbi.nlm.nih.gov/pubmed/32106810
http://dx.doi.org/10.1186/s12865-020-0337-5

Ejemplares similares